Project Title

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura.

Project Summary

The purpose of this study is to determine whether fostamatinib is safe and effective in treating patients with persistent/chronic Immune Thrombocytopenic Purpura (ITP) over a 5 year period.

Blood Disorder

• Immune Thrombocytopenic Purpura

Patient Recruitment Details

Patient recruitment status: Closed

Number of Patients (globally)

124 participants.

Back to Archived Projects...